Vimarsana
Biggest News Aggregation in the World

Page 13 - Biocon Biologic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biocon Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biocon Biologic Today - Breaking & Trending Today

Biocon Q3FY22 revenue at Rs 2,223 crore, up by 18% - Vimarsana News

Biocon Q3FY22 revenue at Rs 2,223 crore, up by 18%

Biocon, a global biopharmaceuticals company, announced its consolidated financial results for the third quarter ended December 31, 2021, on Thursday night.Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, ...

Biocon Q3FY22 revenue at Rs 2,223 crore, up by 18% - Vimarsana News

Biocon Q3FY22 revenue at Rs 2,223 crore, up by 18%

Biocon, a global biopharmaceuticals company, announced its consolidated financial results for the third quarter ended December 31, 2021, on Thursday night.

Biocon posts Q3FY22 revenue at Rs 2,223 Cr - Vimarsana News

Biocon posts Q3FY22 revenue at Rs 2,223 Cr

PBT for the quarter stood at Rs 269 crore

Viatris and Biocon Biologics Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies - Vimarsana News

Viatris and Biocon Biologics Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies

Nov. 3, 2021 Viatris Inc. and Biocon Biologics Limited , a subsidiary of Biocon Ltd., are proud to confirm that Prime Therapeutics, a leading pharmacy benefit manager serving... | November 3, 2021

Biocon Q2FY22 revenue up by 10% at Rs 1,945 crore - Vimarsana News

Biocon Q2FY22 revenue up by 10% at Rs 1,945 crore

Biocon, the global biopharmaceuticals company of India, on Friday said its Q2FY22 revenue growth was up by 10 per cent at Rs 1,945 crore, primarily driven by good performance of the Research Services and Biosimilars business segments.Announcing ...